Clinical Trial Update: A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial of ramucirumab with capecitabine and cisplatin in metastatic gastric/GEJ adenocarcinoma completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Capecitabine (capecitabine)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: COMPLETED | Results posted: 2018-05-02